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Abstract
Background: The Guidelines International Network (G-I-N) aims to promote high quality clinical guideline
development and implementation. Guideline-based performance measures are a key implementation tool and
are widely used internationally for quality improvement, quality assurance, and pay for performance in health
care. There is, however, no international consensus on best methods for guideline-based performance
measures. In order to address this issue, the G-I-N Performance Measures Working Group aimed to develop a
set of consensus-based reporting standards for guideline-based performance measure development and
re-evaluation.
Methods: Methodology publications on guideline-based performance measures were identified from a systematic
literature review and analyzed. Core criteria for the development and evaluation process of guideline-based
performance measures were determined and refined into draft standards with an associated rationale and description
of the evidence base. In a two-round Delphi-process, the group members appraised and approved the draft standards.
After the first round, the group met to discuss comments and revised the drafts accordingly.
Results: Twenty-one methodology publications were reviewed. The group reached strong consensus on nine
reporting standards concerning: (1) selection of clinical guidelines, (2) extraction of clinical guideline recommendations,
(3) description of the measure development process, (4) measure appraisal, (5) measure specification, (6) description of
the intended use of the measure, (7) measure testing/validating, (8) measure review/re-evaluation, and (9) composition
of the measure development panel.
Conclusions: These proposed international reporting standards address core components of guideline-based
performance measure development and re-evaluation. They are intended to contribute to international reporting
harmonization and improvement of methods for performance measures. Further research is required regarding validity,
acceptability, and practicality.
Keywords: Guideline, Guideline adherence, Performance measure, Quality indicator, Reporting standard, Process
assessment (health care), Delphi technique
Background
Clinical practice guidelines aim to improve the quality of
patient care [1]. The Institute of Medicine (IOM) defines
quality of health care as “the degree to which health ser-
vices for individuals and populations increase the likeli-
hood of desired health outcomes and are consistent with
current professional knowledge” [2], implying a dynamic
relation between structure, process, and outcome [3, 4].
The development and use of performance measurement
is recommended as one important way to reach im-
provement [1]. During the last decade, an exponential
increase in the number of performance measures (PM)
used in health care has occurred, leading to concerns
about their trustworthiness and usefulness [5]. In 2012,
more than 2000 PM were published via the National
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Quality Measures Clearinghouse, tenfold more than in
2003 [5].
Existing guidance on PM development or appraisal
highlights that clinical guidelines are an important
source for quality measures [6–11]. From a guideline im-
plementation perspective, PM are important tools as
they enable standardized measurement of the extent of
implementation and the effectiveness of specific recom-
mendations contained within guidelines [12, 13]. We
lack, however, any international consensus as to the
most appropriate methods for guideline-based PM
[14, 15].
The Guidelines International Network (G-I-N) (http://
www.g-i-n.net/) aims to lead, strengthen, and support
collaboration in guideline development, adaptation, and
implementation [16]. In 2012, a working group on PM
was set up to bring guideline and PM developers to-
gether. The G-I-N PM working group (PMWG) con-
sisted of 30 members of organizations producing or
evaluating guideline-based PM from 13 countries in 5
continents. Approximately two thirds were mainly
guideline and one third mainly PM experts. The group
considered that the promotion of a high-quality
guideline-based PM methodology required a set of “best
practice” reporting standards. This paper presents the
consensus of our group on reporting standards and de-
scribes the methods used to develop them.
Methods
(The methods are described in detail in the study proto-
col; see Additional file 1).
Literature review and identification of core criteria
In order to identify candidate core criteria, we searched
for relevant publications on the development of guide-
line based PMs. We identified one systematic review,
judged to be of good quality using the AMSTAR check-
list [17], with 48 publications on guideline-based PM
[14] (appraisal results in Additional file 2). We consid-
ered all publications included in this review and agreed
16 as relevant for this work, described in the original re-
view as “methods papers.” As the review search ended
on 22/04/2010, we performed specific update searches in
Medline via PubMed from 23/04/2010 to 08/12/2013
using the same search strategy (see Table 1) [14]. We in-
cluded methodology publications for guideline-based
PM in English, French, and German. Additionally, we
reviewed the currency of web-based guidance manuals
for PM development in November 2013 and included
hand-searched publications, suggested by two members
of the PMWG.
The steps of guideline-based PM development set out
in the review were used to identify potential core report-
ing criteria [14]. The criteria were critically reviewed,
refined, and complemented as well as supplemented
with rationales by MN, TS, and BS based on the results
of the review and the update search. The draft set of cri-
teria and attendant rationales was initially reviewed by
four international experts from AHRQ (Agency for
HealthCare Research and Quality), AWMF (Association
of the Scientific Medical Societies in Germany), SIGN
(Scottish Intercollegiate Guidelines Network), and the
Heart and Stroke Foundation of Canada.
Delphi process
In the next step, we invited the members of the PMWG
to a Delphi process, a written formal technique for
reaching a consensus in a group of experts. It is charac-
terized by the use of structured questionnaires and for-
mal feedback of the group result, summarizing the
answers and comments to each question. It usually re-
quires at least two rounds allowing individual partici-
pants to reconsider their views in the light of the group
decision and arguments [18]. We used an online survey.
In the first round, participants were asked to rate each
criterion and rationale on a four-point Likert-type scale
“I agree, I rather agree, I rather disagree, I disagree” and
Table 1 Search strategy for guideline-based performance mea-
sures used by Kötter et al. 201214
Quality indicators Clinical guidelines Development
1. quality indicator$.tw 12. guideline$.tw 31. develop$.tw
2. quality criterion$.tw 13. practice guideline/ 32. and\11,30,31








6. outcome measure$.tw 17. guidance$.tw
7. outcome indicator$.tw 18. directive$.tw
8. audit.tw 19. health service$
research.tw
9. outcome assessment.tw 20. evidence based
medicine.tw
10. process assessment.tw 21. quality assessment.tw
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in addition, to rate the importance of each criterion on a
respective Likert Scale (critically important, important,
minor important, not important). To reach consensus,
the overall agreement for a criterion implied at least
75 % of participants to have scored “agree” or “rather
agree.” Group members could also give comments and
propose modifications as well as additional criteria
which they considered being essential. Results were dis-
cussed in a PMWG meeting. In the second round, par-
ticipants were again asked to rate agreement and
importance.
Results
In total, 21 methodology publications were included.
Sixteen methodology publications were identified by the
authors of the systematic review [14]; these were agreed
as being relevant to this work [19–34]. The update
search yielded three additional methodology publications
[35–37]. Two publications reporting approaches to
guideline-based PM from Netherlands and Germany
were contributed by PMWG members [8, 38] (see
Fig. 1).
One criterion (topic selection) included in the system-
atic review [14] was excluded for our purposes as not
being core to guideline-based PM reporting. A further
two criteria were added (3 and 4), based on our own ex-
perience and knowledge and accepted best practice in
PM development. Another criterion (specification of
PM) was added as the result of the experts’ comments.
Thus, nine criteria were proposed.
Of the 30 experts invited to participate in round 1,
90 % responded and 70 % (21/30) completed the online
Delphi questionnaire. The 27 respondents of round 1
were invited to take part in round 2. Of those, 44 % (12/
27) completed the rating of the criteria and approved
the rationales (see Additional files 3 and 4). Editorial
changes during the publication process were approved
by the group.
In Delphi round 1, more than 75 % overall agree-
ment was reached for all criteria (between 77 and
100 % per criterion scored with “agree” or “rather
agree”). No additional criteria were proposed. The
main outcome of the discussion in between the Del-
phi rounds was the need for consistent wording
Fig. 1 Literature review and consensus process for reporting criteria on guideline-based performance measures
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expressing the goal of developing reporting standards
as opposed to developing a quality appraisal tool. Re-
vision of the criteria was made accordingly. In Delphi
round 2, the overall agreement for every revised cri-
terion and rationale was at least 90 % (see Table 2).
The importance awarded for the criteria varied, but
consensus was reached for the importance with more
than 75 % of the participants rating all criteria as
“very important” or “rather important” (see Fig. 2).
Based on these results and subsequent editing to align
these standards with wording in other reporting stan-
dards [67], the G-I-N PMWG presents the following
reporting standards for guideline-based performance
measures (see also Table 2).
1. Guideline selection
a. State the currency of the guideline(s) used for per-
formance measure development and state if it/they meet
Table 2 Criteria for development of guideline-based performance measures, supporting methodology publications and strength of
consensus at Delphi round 2
Criterion Supporting methodology publications as
identified by systematic search
Strength of consensus
1. Guideline selection
1a. State the currency of the guideline(s) used for guideline-based
performance measure development and state if it/they meet the criteria
set out by the Guidelines International Network (G-I-N). Describe the
guideline quality using a validated guideline appraisal tool, such as AGREE II.
b. Indicate additional sources, if used and the rationale for their use.
AQUA 2013 [35]Campbell 2002 [22]1b: ACCF/
AHA 2005 [28]/2010 [37] ÄZQ 2009 [24]
Graham 2009 [27] Hutchinson 2003 [30]
Overall agreement
100 % Agree 67 %
Rather agree 33 %
2. Selection of guideline recommendations
State the strength of evidence and/or the grade of recommendation
qualifying the guideline recommendations to be used for guideline-based
performance measures.
AHCPR 1995 [20]AHCPR 1995 [19]ACC/AHA
2005 [28]/2010 [37]ÄZQ 2009 [24] AQUA 2010
[23] /2013 [35] Baker 1999 [21] Bergman 1999
[25] Califf 2002 [26] Campbell 2002 [22] Duffy
2005 [32] Graham 2009 [27] Hutchinson 2003
[30] De Koning 2006 [8] Wollersheim 2003 [29]
Overall agreement
100 % Agree 75 %
Rather agree 25 %
3. Selection process of performance measures from guideline
recommendations
Describe clearly and in detail the methods used to develop the
performance measures from the supporting clinical guideline
recommendations.
ACC/AHA 2005 [28]ACCF/AHA 2010 [37]ÄZQ
2009 [24]AQUA 2010 [23]/2013 [35] Califf 2002
[26] Campbell 2002 [22] Campbell 2011 [36]
Duffy 2005 [32] Hutchinson 2003 [30] De
Koning 2006 [8] LaClair 2001 [34]
Overall agreement
100 % Agree 92 %
Rather agree 8 %
4. Core attributes of performance measures
State, if the following attributes within the development
process of guideline-based performance
measures were considered:
• Relevance (as a minimum: potential for improvement/clinical relevance)
• Scientific Soundness (as a minimum: the evidence supporting the measure)
• Feasibility (as a minimum: clarity of definition and measurability)
ACC/AHA 2005 [28] ACCF/AHA 2010 [37] ÄZQ
2009 [24] Baker 1995 [21] Califf 2002
[26]Graham 2009 [27] Campbell 2002 [22]
Campbell 2011 [36]Duffy 2005 [32] Golden
2008 [33] Wollersheim 2003 [29]
Overall agreement
100 % Agree 92 %
Rather agree 8 %
5. Specification of performance measuresState that numerator and
denominator of the guideline-based Performance Measure is specified
unambiguously and in detail.
ACCF/AHA 2005 [28]Advani 2003 [31]ÄZQ
2009 [24]AQUA 2010 [23] /2013 [35]Campbell
2002 [22] Campbell 2011 [36] Golden 2008
[33]LeClair 2001 [34]
Overall agreement
100 % Agree 100 %
6. Intended use of performance measuresState if there is a clear
description of the intended use of the performance measure (quality
improvement, quality assurance with or without accountability
purposes, pay for performance) and at what level in the health
system it is used (local, regional, national).
ACCF/AHA 2010 [37]ÄZQ 2009 [24]AQUA 2013
[35 Campbell 2002 [22] Campbell 2011 [36]
Overall agreement
100 % Agree 75 %
Rather agree 25 %
7. Practice test of performance measures
If a practice test (piloting) is carried out prior using the guideline-based
performance measure, provide a full description of the process.
If no practice test is done, provide the rationale for this.
Provide information about any other validation process in use.
AHCPR 1995 [20] AHCPR 1995 [19]AQUA 2013
[35] Campbell 2011 [36] ACCF/AHA 2005 [28]
Golden 2008 [33] Wollersheim 2003 [29]
Overall agreement 1
00 % Agree 75 %
Rather agree 25 %
8. Review and reevaluation of performance measuresReport the
currency of the performance measures in use. State if there are criteria
for deciding to change or stop using performance measures.
Graham 2009 [27]ACCF/AHA 2010 [37]Duffy
2005 [32]Follmann 2012 [38]
Overall agreement 92 %
Agree 75 % Rather
agree 17 % Rather
disagree 8 %
9. Composition of the panel deciding on guideline-based performance
measuresDescribe clearly the composition of the panel deciding on
guideline-based performance measures with information on
participation of multidisciplinary experts, stakeholders in the field,
experts in quality measurement, and patient representatives.
ACCF/AHA 2005 [28] ÄZQ 2009 [24] AQUA
2010 [23] /2013 [35]Campbell 2002
[22]Campbell 2011 [36]Duffy 2005 [32]
Hutchinson 2003 [30] Wollersheim 2003 [29]
Overall agreement
100 % Agree 92 %
Rather agree 8 %
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the criteria set out by the Guidelines International Net-
work (G-I-N). Describe the guideline quality using a vali-
dated guideline appraisal tool, such as AGREE II.
b. Indicate additional (evidence) sources, if used and
the rationale for their use.
Rationale
To provide a high quality, trustworthy base for PM,
the source clinical guideline should meet the criteria
published by G-I-N [39] (i.e., use of a multidisciplin-
ary development group, description of the decision-
making process and its methods, declaration and
management of conflicts of interest, systematic evi-
dence reviews, and clear wording of recommenda-
tions). In order to objectively evaluate the guideline
quality and allow comparison against other source
guidelines, a validated appraisal instrument (preferably
the Appraisal of Guidelines for Research and Evalu-
ation (AGREE) instrument II [13]) should be used; in
the case of guideline adaptation an internationally ac-
cepted instrument, preferably ADAPTE [40] is recom-
mended. A crucial fact to consider is the currency of
the guideline to ensure consistency with the actual
evidence base of guideline recommendations under
consideration for the development of performance
measures. In case of doubt, an update search of the
literature is recommended [41].
Existing PM should also been taken into account as
evidence sources when developing “new” indicators.
There are national and regional databases and other
sources for existing PM. If additional evidence sources
are used, the rationale for their use should be clearly
stated.
A full description and quality appraisal of the under-
lying guideline resource and, if applicable, the citation of
other evidence resources are not currently standard
practice in publications of guideline-based PM which are
not developed simultaneously with a guideline. In
addition, only about half of the publications of the sys-
tematic review provide a methodological quality ap-
praisal of the guidelines used [14].
2. Selection of guideline recommendations
State the quality of evidence and/or the strength of rec-
ommendation qualifying the guideline recommendations
to be used for performance measure development.
Fig. 2 Assessment of importance of the reporting criteria
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Rationale
PM are based on specific guideline recommendations or
objectives for care. Recommendations predominantly ad-
dress health care processes (e.g., diagnostic and thera-
peutic interventions) which ideally are under the control
of health care professionals. Structures and outcomes of
care are more determined by influencing systemic fac-
tors and regional or national conditions [42].
Internationally, there is debate about the type of rec-
ommendations which are adequate sources for PM. Rec-
ommendations with a strong grade of recommendation
(“we recommend,” “do,” “should be done” or “we don’t
recommend,” “don’t do,” “should not be done”) are
meant to be useful and valid for the majority of patients
whereas weak recommendations describe options for in-
dividual situations. Recommendations with a weak grade
of recommendation (“we suggest,” “probably do,” “can
be considered,” “might be done”) are therefore not con-
sidered suitable for PM intended to serve for external
quality assurance, in particular accountability purposes
(e.g., pay for performance). The strength of a recommen-
dation does not only express the level of the underlying
evidence but also other considerations like the level of
confidence that implementing this recommendation will
do more good than harm or will avoid harm in case of
negative recommendations [43, 44]. Strong recommen-
dations should ideally be based on high quality evidence,
but if evidence is of poor quality or absent, which is the
reality for various aspects in health care that are most
important for patients, a strong expert consensus might
also be considered as a source for a guideline-based PM,
given this was reached by a multidisciplinary panel using
formal techniques to reduce the risk of bias [9, 22, 24].
However, the inherent uncertainty about the effects of
such PM requires their piloting before broader imple-
mentation (see criterion 7).
Levels of evidence and/or grade of recommendations
of the underlying guideline recommendation are pro-
vided in about two third of respective publications [14].
3. Selection process of performance measures from
guideline recommendations
Describe the consensus methods used to select the per-
formance measures from the supporting clinical guide-
line recommendations in detail.
Rationale
The process of selection implies specification of candi-
date PM (see criterion 5), critical appraisal according to
the specific criteria or core attributes (see criterion 4),
and final decision-making by an expert panel (see criter-
ion 9) in a consensus process. To minimize bias, it is
recommended to use formal consensus methods [8, 22–
24, 26, 28, 30, 32, 34–37].
Appraisal of guideline-based PM should be done in
several steps. Some attributes can be appraised directly,
before implementing the measure (see criterion 4);
others can only be appraised when there are already data
of the respective measure available (e.g., reliability,
validity).
Reporting the consensus methods used for selection
and how they were conducted helps to assess the quality
of the selection process. To our knowledge, there are
presently no studies comparing different selection
methods. The majority of publications identified stated
the use of formal consensus methods to develop PM.
Nearly half of the studies available cite the Research and
Development Corporation (RAND) Appropriateness
Method (RAM) developed by the RAND and the Uni-
versity of California, Los Angeles (UCLA) or a modified
RAM using the consensus method with varying appraisal
criteria and cutoff levels for agreement. Also mentioned
is a RAND-modified Delphi method or a Delphi process
[14].
4. Core attributes of performance measures
State the consideration of the following attributes during
the performance measure development process:
 Relevance (as a minimum: potential for
improvement/clinical relevance)
 Scientific Soundness (as a minimum: the evidence
supporting the measure)
 Feasibility (as a minimum: clarity of definition and
measurability)
Rationale
Frequently reported appraisal criteria in the methodology
publications include usefulness of PM for improving pa-
tient outcomes, relevance, and feasibility of monitoring
[20, 22, 24, 26, 28, 32, 35, 37]. A comparison of inter-
nationally used PM appraisal criteria found the criteria
“relevance” or “needs assessment”/prioritization as well as
clarity of definitions, feasibility, reliability, and validity in
all four national approaches analyzed [35] (the Quality
and Outcomes Framework (QOF) led by the UK National
Institute for Health and Care Excellence (NICE), the Ger-
man appraisal instrument QUALIFY by the Institute for
Quality and Patient Safety, the approach of the approach
of the American-based National Quality Forum and the
criteria used by the Royal Australian College of General
Practitioners). Acceptability was stated as criterion in two
of them [36]. A further national indicator assessment
tool—the Dutch “Appraisal of indicators through research
and evaluation” (AIRE) instrument, does not name “rele-
vance” but covers feasibility as well as reliability and valid-
ity [8]. The US National Quality Measures Clearinghouse
suggests categorizing the attributes of PM in three
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domains: (1) importance, (2) scientific soundness, and (3)
feasibility [45]. Where feasibility and most scientific
soundness criteria (e.g., reliability and validity) can only be
verified through a practice test, the importance or rele-
vance of a measure, its clarity of definition (defining nu-
merator and denominator unambiguously), and the
evidence supporting the measure might be assessed by ex-
perts without specific PM data [24].
Given different possible perspectives, developers
should explain which aspects they summarize under
“relevance” or “importance” of a measure” (e.g., potential
benefit for improvement of patient outcomes, relevance
for the specific health system, cost saving, etc.). Further
appraisal and selection after having done a practice test
(e.g., does it measure what it should measure—reliability
and validity, as well as feasibility in current systems) is
reasonable. If a recommendation is potentially measur-
able, the lack of measurement feasibility in current
health information systems should not be used as the
sole criterion for determining a measure to be invalid as
improvements to existing data can result in a measure
becoming feasible.
5. Specification of performance measures
Specify the performance measure numerator and de-
nominator unambiguously and in detail.
Rationale
To be measurable, a guideline recommendation has
to be transformed into a rate or proportional based
measure consisting of numerator and denominator.
Only in a few cases, PM consist of so-called sentinel
events which should be presented as counts, rather
than proportions—for example, maternal deaths [22].
Inclusion criteria for the denominator have to specify
the patient characteristics (e.g., age, gender, stage, or
severity of disease, having had a certain treatment
already) in a way that patients to be included can
clearly be identified and data—ideally in an electronic
system, can be collected. The same specifications have
to be made for the numerator: the diagnostic test or
therapeutic intervention has to be described and spe-
cified clearly without ambiguity. In addition, the spe-
cific date or period of measurement has to be noted.
For all specifications, a list of data fields has to be set
up to ensure an adequate and consistent documenta-
tion. This list should be provided as accompanying
information for each PM. It is also crucial to define
possible exceptions for both numerator and denomin-
ator (e.g., age, contraindications, technical obstacles,
patient wish). If possible, PM should be integrated
into existing coding and data systems, as parsimoni-
ous PM and data use is an important goal.
Example of a rate based measure
Recommendation: For patients with R0 resected stage III
colon cancer, adjuvant chemotherapy is indicated. (Level
of Evidence 1a, strong consensus)
Numerator: Number of patients who have undergone
adjuvant chemotherapy.
Denominator: All patients with colon cancer Union
internationale contre le cancer (UICC) stage III who
have had an R0-resection of the primary tumor.
Further specification: substances, minimal number of
chemotherapy cycles required, timeframe.
Exceptions: Patient refusal, contraindications to be
specified.
6. Intended use of performance measures
Provide a clear description of the intended use of the
performance measure (e.g., quality improvement, quality
assurance with or without accountability purposes as
pay for performance, public reporting) and at what level
in the health system it is used (local, regional, national).
Rationale
The intended use of guideline-based PM should be
stated as PM are to be used at different levels within
health systems:
(a)Quality improvement (QI)—for internal quality
improvement purposes such as voluntary initiatives
of health professionals (e.g., local clinical audit, peer
review)
(b)Accountability—containing different aspects, for
example:
– Certification: for quality assurance at a regional
or national level, such as being used as a
compulsory instrument for quality assurance in
hospitals and/or a defined ambulatory care
setting or for various aspects of the in- and/or
out-patient sector in general [46]. Important as-
pects of the use of such PM are benchmarking
and public reporting [47].
– Pay for performance, where payment is attached
to defined levels of achievement of the measure
with the intention of improving the quality of
care [48, 49].
In addition, quality measures may be used in research
to develop or produce new knowledge about the health
care system.
The different uses of PM influence the indicator devel-
opment methods that have to be applied. It seems useful
to distinguish PM into those to be used for QI and those
used for accountability purposes [50, 51]. A key differ-
ence between measures developed for quality improve-
ment and those developed for public reporting or
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accountability purposes is that the requirements for val-
idity and reliability are more complex for the latter as
they include different denominators (population based
vs local patient based rates) [11]. Accountability mea-
sures require that each provider collects data in exactly
the same way through standardized and detailed specifi-
cations. This ensures that one is confident that a prede-
fined measure of performance has been achieved and/or
that comparisons of performance between providers are
fair. Beyond that, risk adjustment is essential. It is used
to compensate for factors like age and health burden-
related differences in the patient mix at various sites in
order to make the results from different sites fairly com-
parable [9, 22]. Thus, it is important that the rigor of
PM development (as assessed by 4 and 5) reflects their
intended use in the health system [50, 52].
7. Practice test of performance measures prior to their
broader implementation and routine use
Provide a full description of the practice test (piloting)
prior to using the guideline-based performance measure.
If no practice test is done, provide the reason for this.
Provide information about any other validation process
in use.
Rationale
All measures but especially indicators that are used
for regional or national reporting purposes or pay for
performance are at risk of having unintended conse-
quences [53, 54]. A practice test offers the opportun-
ity to identify such unintended consequences early.
Practice tests are recommended in the early methods
concepts for guideline-based PM by Agency for
Health Care Policy and Research (AHCPR) [11, 19,
20, 55], and testing is described in the AHRQ-report
of Performance Measure Development 2011 [11, 19,
20, 55]. There is no standard definition of what a
practice test has to contain. A comprehensive piloting
method was introduced to the nationwide UK Quality
and Outcomes Framework (QOF) after experience of
unintended consequences without such a procedure
[36, 56]. Another nationwide PM program includes a
three step piloting and practice test [35]. Practice
tests (piloting) of guideline-based PM are only de-
scribed in a minority of published projects [14, 57].
The methods chosen for the practice test should be
in accordance with the intended use of the measures
(see 4). It should be done before the final decision of
use is made. It is recommended that testing should
be done in a representative “real world” setting. The
process for final decision-making to use or not to use
the PM should be transparent. PM require monitoring
when implemented in order to evaluate their longer
term appropriateness.
8. Review and reevaluation of performance measures
State the currency of the performance measures in use.
State the criteria for deciding to change or stop using
performance measures.
Rationale
There can be several reasons to stop a measurement, for
example, if measures show unintended consequences or
lack of reliability [35]. Other reasons to reconsider the
use of an indicator are given if the evidence base chan-
ged or if the defined performance “benchmarks” are
reached and are stable over a defined period of time [37,
38, 58]. In order to promote transparency, “stop” criteria
should be stated explicitly. If data are available, ideally,
the underlying guideline and the PM should be updated
simultaneously [38].
9. Composition of the panel deciding on guideline-based
performance measures
Describe clearly the composition of the panel deciding
on the performance measures with information on par-
ticipation of multidisciplinary experts, stakeholders in
the field, experts in quality measurement, and patient
representatives.
Rationale
Similar principles apply to the composition of guideline-
based PM groups as to clinical practice guidelines, in-
cluding the consideration of conflicts of interest, but
there is very little evidence for this rationale. According
to the “good practice,” the group should be multidiscip-
linary and include content experts in the field—usually
health care professionals involved in the relevant clinical
guideline development including stakeholders who are
being measured and, if applicable and possible stake-
holders who will use this data to inform decisions, pa-
tient representatives and experts in quality measurement
(representing the organizations which measure) [13].
This is also a criterion of the Dutch AIRE instrument
[59]. Only a few studies named the individual members
of the panels [14] whereas criteria for their selection
(e.g., clinical or methodological expertise, membership
in a specialist society) were reported in most of the stud-
ies. Patient participation during the development process
was only reported in few studies, in all of these patients
participated directly in the panels. No study reported on
patient participation during guideline selection and the
extraction of recommendations [14]. The best method of
involving patients remains a subject for further research
[60].
Discussion
We have developed a reporting standard for guideline-
based PM with nine criteria, using formal written
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consensus methods (two Delphi rounds). This is the first
work to our knowledge presenting a consensus on trans-
parent reporting of methodological requirements of
guideline-based PM by an international group. Applying
these criteria aims to make guideline-based PM more
comprehensible and valuable. The fact that all criteria
were confirmed after the first round indicates their inter-
national meaningfulness for the participating guideline
and PM experts. There was a strong view on these cri-
teria to be used as standard reporting criteria. The group
judged the available evidence not yet sufficient for the
development of an appraisal tool.
The methodology publications identified were het-
erogeneous concerning criteria for guideline selection,
selection of guideline recommendations, panel selec-
tion, consensus methods, appraisal criteria, and pro-
posals for practice tests. No paper included and
specified all nine criteria presented here. In light of
missing comparative studies, the structured consensus
process was most important to ensure the best pos-
sible expert-based PM reporting criteria. It is notable
that one of the steps in PM development identified in
the systematic review [14]—“topic selection”—was not
included in the reporting standard. The rationale for
this was that while it was judged essential to assess
potential PM based on guideline recommendations
according to their relevance for health care (see cri-
terion 4), topic selection should occur before
guideline-based PM development starts. In general,
prevalence, burden of disease, and potential of im-
provement are well-accepted criteria for topic selec-
tion of clinical guidelines [61, 62].
We identify the following limitations of this work:
First, the present criteria do not address any qualitative
aspects of patient care to be reported. It is recognized
that different patient groups do have different needs and
the best quality of care may be different for the same
condition, requiring differentiated patient-oriented
measures (for example, for patients with multiple
morbidities) [63]. Second, we also do not address out-
come measurement development and therefore patient
reported outcome measures, including quality of life
measures are not mentioned [64]. Guideline-based pa-
tient reported outcomes or quality of life measures are
up to now almost completely missing in guideline-based
PM [65]. Third, there was no consideration of cost-
effectiveness to be a criterion for the use of a guideline-
based PM [66]. For these aspects, further research is
required.
Furthermore, the consensus process was done with a
small group of experts with a low participation rate in
the second round. However, there was a high acceptance
already in the first round and the final draft was ap-
proved by the whole group.
Finally, not all criteria were judged to be of similar im-
portance (see Fig. 2).
It is planned that the reporting standards will be tested
in different countries and settings in order to evaluate
their validity, acceptability, and practicality.
Conclusion
These reporting standards provide international consen-
sus on the best practice criteria for reporting guideline-
based PM development and re-evaluation. Better report-
ing of methods used by PM developers should improve
both the quality and consistency of guidelines-based
PM. The PMWG encourages research on the validity,
acceptability, and practicality of the respective criteria.
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